Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.53 |
| ▸ | CA2 | P00918 | 14/20 | 0.53 |
| ▸ | CA9 | Q16790 | 10/20 | 0.48 |
| ▸ | CA12 | O43570 | 8/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
| ▸ | CA6 | P23280 | 3/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7635664 | 0.83 | ALDH1A1 (0.52) | CA1CA2F2PRSS1PRSS2 | |
| SCHEMBL31670545 | 0.82 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL67270 | 0.82 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL7913940 | 0.80 | CA1 (0.64) | CA1CA2CA9CA12CA7 | |
| SCHEMBL271385 | 0.79 | L3MBTL1 (0.52) | CA1CA2CA9CA12CA6 | |
| SCHEMBL9796322 | 0.79 | CA2 (0.64) | CA1CA2CA9CA12CA7 | |
| SCHEMBL5274755 | 0.78 | CA2 (0.64) | CA1CA2CA9CA12CA7 | |
| SCHEMBL30230622 | 0.78 | CA2 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1805285 | 0.78 | CA2 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL3781504 | 0.77 | STAT3 (0.56) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | ASUBIO PHARMA CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7618977-B2 | Method of treating dermatitis comprising administering a chymase inhibitor | ASUBIO PHARMA CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1459888-B1 | Planographic printing plate precursor | FUJIFILM CORP (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1142586-B1 | USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-7169951-B2 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1174151-B1 | THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| EP-1192950-B1 | THERAPEUTIC DRUGS FOR DERMATITIS EXHIBITING A BIPHASIC SKIN REACTION CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1114035-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-6921766-B1 | Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-26 | — | — | US | disclosed |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| US-20020183339-A1 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020183338-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | ASUBIO PHARMA CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| EP-1192950-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR DERMATITISES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192949-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1174151-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR VARIOUS EOSINOPHILIA-RELATED DISEASES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1142586-A1 | INHIBITORS AGAINST VASCULAR LIPID DEPOSITION CONTAINING CHYMASE-INHIBITING SUBSTANCES | SUNTORY LIMITED (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1114035-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNTORY LIMITED (JP) | 2001-07-11 | — | — | EP | disclosed |
| US-6051361-A | PHOTOSENSITIVE MIXTURE COMPRISING A COMPOUND CAPABLE OF GENERATING AN ACID ON EXPOSURE OF ACTINIC LIGHT, A COMPOUND CAN BE CROSSLINKING BY AN ACID, AN INFRARED ABSORBER AND AN ADDITIONAL POLYMER | KONICA CORPORATION (JP) | 2000-04-18 | — | — | US | disclosed |
| WO-2000010982-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEROF | SUNTORY LIMITED (JP) | 2000-03-02 | — | — | WO | disclosed |
| EP-0903225-A2 | Light sensitive composition and image forming material | KONICA CORPORATION (JP) | 1999-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183339-A1 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | CMA1, SERPINB1, TSLP | CA1 904/4885CA2 159/4885CA9 978/4885 |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | CMA1, ACE, ACE2 | CA1 1395/4885CA2 71/4885CA9 114/4885 |
| US-20020183338-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | CMA1, MMP1, SERPINB1 | CA1 2655/4885CA2 426/4885CA9 345/4885 |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | CMA1, DNPEP, SERPINB1 | CA1 632/4885CA2 142/4885CA9 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.